Lupin: Strong quarterly results, great management commentary Strong Fundamentally and focus on innovations 3rd largest generic company in USA Breaking 10 year high. Initiating buy position with 3600 target in short term
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.